Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer

International Journal of Cancer

Volumn 141, Issue 4, 2017, Pages 701-710

  Clarke, Megan A ^a   Luhn, Patricia ^b   Gage, Julia C ^a   Bodelon, Clara ^a   Dunn, S Terence ^c   Walker, Joan ^c   Zuna, Rosemary ^c   Hewitt, Stephen ^a   Killian, J Keith ^a   Yan, Liying ^d   Miller, Andrew ^d   Schiffman, Mark ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d EpigenDx   (United States)

Author keywords

cervical cancer; human papillomavirus; methylation; next generation sequencing; pyrosequencing

Indexed keywords

BISULFITE; FORMALDEHYDE; MICRORNA 124; MYOD1 PROTEIN; PARAFFIN; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR SOX1; TRANSCRIPTION FACTOR SOX17; TUMOR MARKER;

ADCYAP1 GENE; ADULT; AGED; ARTICLE; ASCL1 GENE; ATP10 GENE; CADM1 GENE; CANCER GRADING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTODIAGNOSIS; DBC1 GENE; DCC GENE; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; EPB41L3 GENE; FEMALE; GENE; GENE IDENTIFICATION; GENETIC ANALYSIS; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HS3ST2 GENE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LIQUID BASED CYTOLOGY; LOOP ELECTROSURGICAL EXCISION PROCEDURE; MAL GENE; MARKER GENE; MICROARRAY ANALYSIS; MOS GENE; MYOD1 GENE; NEXT GENERATION SEQUENCING; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SOX1 GENE; SOX17 GENE; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; TISSUE FIXATION; TMEFF2 GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS; AREA UNDER THE CURVE; DNA MICROARRAY; DNA SEQUENCE; EARLY CANCER DIAGNOSIS; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; CPG ISLANDS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85019667459     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30781     Document Type: Article

References (50)

1. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30Suppl5:F107–16.
2. Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76 Suppl 1:S49–55.
3. Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293–9.
4. Lai HC, Lin YW, Huang RL, et al. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 2010;116:4266–74.
5. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011;17:2459–65.
6. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011;129:2218–25.
7. Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL, promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013;133:1293–9.
8. De Strooper LM, Hesselink AT, Berkhof J, et al. Combined CADM1/MAL methylation and cytology testing for colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol Biomarkers Prev 2014;23:1933–7.
9. Hesselink AT, Heideman DA, Steenbergen RD, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014;135:880–6.
10. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, et al. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol 2014;132:709–14.
11. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014;15:315–22.
12. Louvanto K, Franco EL, Ramanakumar AV, et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer 2015;136:E638–45.
13. De Strooper LM, Verhoef VM, Berkhof J, et al. Validation of the FAM19A4/mir124–2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol 2016;141:341–7.
14. Eijsink JJ, Lendvai A, Deregowski V, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012;130:1861–9.
15. De Strooper LM, Meijer CJ, Berkhof J, et al. Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2/3 lesions. Cancer Prev Res (Phila) 2014;7:1251–7.
16. Verhoef VM, van Kemenade FJ, Rozendaal L, et al. Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. Gynecol Oncol 2015;137:55–9.
17. Sova P, Feng Q, Geiss G, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:114–23.
18. Wang SS, Smiraglia DJ, Wu YZ, et al. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 2008;68:2489–97.
19. Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 2008;123:161–7.
20. Lendvai A, Johannes F, Grimm C, et al. Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. Epigenetics 2012;7:1268–78.
21. Boers A, Wang R, van Leeuwen RW, et al. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics 2016;8:29.
22. Chen YC, Huang RL, Huang YK, et al. Methylomics analysis identifies epigenetically silenced genes and implies an activation of beta-catenin signaling in cervical cancer. Int J Cancer 2014;135:117–27.
23. Wang SS, Zuna RE, Wentzensen N, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev 2009;18:113–20.
24. Wentzensen N, Schiffman M, Dunn T, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009;125:2151–8.
25. Wentzensen N, Schiffman M, Dunn ST, et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009;124:964–9.
26. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253–66.
27. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16:383–93.
28. Lorincz AT, Brentnall AR, Scibior-Bentkowska D, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer 2016;138:2745–51.
29. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265–75.
30. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168–76.
31. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013;105:1550–7.
32. Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. J Natl Cancer Inst 2015;107:djv257.
33. Clarke MA, Wentzensen N, Mirabello L, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2125–37.
34. Apostolidou S, Hadwin R, Burnell M, et al. DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer 2009;125:2995–3002.
35. Hwang JA, Kim Y, Hong SH, et al. Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis. PLoS One 2013;8:e79634.
36. Jung S, Yi L, Jeong D, et al. The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer. Oncol Rep 2011;25:245–52.
37. Malik MA, Gupta A, Zargar SA, et al. Role of genetic variants of deleted in colorectal carcinoma (DCC) polymorphisms and esophageal and gastric cancers risk in Kashmir Valley and meta-analysis. Tumour Biol 2013;34:3049–57.
38. Meimei L, Peiling L, Baoxin L, et al. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med Oncol 2011;28:282–9.
39. Park HL, Kim MS, Yamashita K, et al. DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer 2008;122:2498–2502.
40. Shin CM, Kim N, Park JH, et al. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. J Pathol 2012;226:654–65.
41. Fu D, Ren C, Tan H, et al. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Med (Baltimore) 2015;94:e637.
42. Sun TT, Tang JY, Du W, et al. Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. Int J Cancer 2015;136:1053–64.
43. Ashktorab H, Rahi H, Wansley D, et al. Toward a comprehensive and systematic methylome signature in colorectal cancers. Epigenetics 2013;8:807–15.
44. Rai R, Sharma KL, Tiwari S, et al. DCC (deleted in colorectal carcinoma) gene variants confer increased susceptibility to gallbladder cancer (Ref. No.: Gene-D-12–01446). Gene 2013;518:303–9.
45. Arantes LM, de Carvalho AC, Melendez ME, et al. Validation of methylation markers for diagnosis of oral cavity cancer. Eur J Cancer 2015;51:632–41.
46. Sartor MA, Dolinoy DC, Jones TR, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011;6:777–87.
47. Patel DA, Rozek LS, Colacino JA, et al. Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. J Virol Methods 2012;184:84–92.
48. De Strooper LM, van Zummeren M, Steenbergen RD, et al. CADM1, MAL and miR124–2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol 2014;67:1067–71.
49. Kagan J, Srivastava S, Barker PE, et al. Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res 2007;67:4545–9.
50. Mikeska T, Cadiloro IL, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics 2010;2:561–73.